Page 1237 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1223

Lindane, 1075 on drug metabolism, 72, 72t Lung cancer, 973–974
Linezolid first-pass effect, 48 Lung maturation, fetal, corticosteroids for,
description of, 823, 824t L-Norgestrel, 728t. See also Progestins 711
tuberculosis treated with, 843t, 848–849 Loading dose, 50–51, 51f Lurasidone, 529t
Linkage disequilibrium, 75t Loa loa, 941 Luteinizing hormone (LH), 668f, 668–669,
Linoleic acids Lobeline, 109, 110f 669t
on arachidonic acid metabolism, 337 Local circuit neurons, 373, 373f chemistry and pharmacokinetics of, 674
description of, 324 Log-kill hypothesis, 950, 950f diagnosis of responsiveness of, GnRH
Liothyronine (T 3 ), 690–692, 701t. See also Lomefloxacin, 838 in, 677
Thyroid drugs Lomitapide, 638 in ovarian function, 721
Lipid Lomustine, 953f, 955t pharmacodynamics of, 674
blood levels of, guidelines, 628, 629t Long QT syndrome Lutropin alfa, 674
diffusion of, 8, 8f molecular and genetic basis of, 233f, Lymphoma
metabolism of, female hormonal 234b, 235t Hodgkin’s, 970
contraceptives on, 733 torsade de pointes in, 234b, 237f non-Hodgkin’s, 970
Lipid:aqueous partition coefficient, 8 Long-term potentiation (LTP), 375 Lynestrenol, 728t. See also Progestins
Lipid resuscitation, 469b Loop diuretics, 191t, 224t, 262f, 262t, Lysergic acid diethylamide (LSD). See also
Lipid-soluble agents, intracellular receptors 262–264, 273t. See also Diuretics Ergot alkaloids
for, 27, 27f kidney injury from, acute, 254, 275 description of, 294, 297t, 577t, 580
Lipodystrophy, 757 with potassium-sparing diuretics, 269 G io protein-coupled receptor activation
Lipoprotein, 626 preparations available, 274t by, 577t, 582–583
high-density, 626, 627–628, 628f with thiazide diuretics, 269
structure of, 627 Loop of Henle, 255f, 256–257, 257f, 263 M
synthesis and catabolism of, 627–628 Loperamide, 568, 1100. See also Opioid Macitentan, 312, 313b, 317t. See also
types of, 626 agonists Endothelin inhibitors
very-low-density, 626, 627, 628f Lopinavir, 872t, 881 Macrobid, 897
Lipoprotein (a) (Lp[a]), 626–627 Loratadine, 283t, 296t. See also H 1 -receptor Macrolides, 818–821, 824t
Lipoprotein disorders, 628–629, 629t antagonists azithromycin, 820, 824t
Lipoprotein lipase (LPL), 627 Lorazepam, 393t. See also Benzodiazepines clarithromycin, 819f, 820, 824t
Liposomal irinotecan, 964 delirium tremens treated with, 391 drug interactions of, 1168t
Lipoxins, 324, 331 ethanol withdrawal treated with, 406t, erythromycin, 819–820, 824t
Lipoxygenase (LOX), 323–325, 325f 585, 589t ketolides, 820–821, 824t
effects of, 332 pharmacokinetics of, 385t, 450t preparations available, 825t
products of, 323–325, 325f seizures treated with, 432, 437t prokinetic activity of, 1098
Liraglutide, 290t, 762, 769t structure of, 382f Macrophage colony-stimulating factor, 997t
Lispo, 768t. See also Insulin Lorcaserin Macugen, 1065
Lithium, 268, 524–528, 529t description of, 289, 296t Macula densa, on renin release, 301
acute major depression treated with, 526 obesity treated with, 289b, 290t Macular degeneration, age-related, 1058,
adverse effects and complications of, 527 Losartan. See also Angiotensin receptor 1065, 1067
bipolar affective disorder treated with, blockers (ARBs) Mafenide acetate, 836
524, 526 heart failure treated with, 220, 222, 224t Magnesium, 247, 251t
in breast milk, 1056 hypertension treated with, 179t, 189, 192t Magnesium citrate, 1098
clinical pharmacology of, 526–528 on renin-angiotensin system, 305 Magnesium hydroxide, 1089, 1098
drug interactions, 527, 1167t Lovastatin, 632–634, 633f, 639t Ma-huang, 1133t
in elderly, 1061 Low-density lipoproteins (LDLs), 165, Maintenance dose, 50, 50b, 51f
maintenance treatment in, 526–527 626, 627, 628f Major depressive disorder (MDD),
monitoring treatment in, 526 Low-molecular-weight (LMW) heparin, 532–536. See also Depression
overdoses of, 527–528 612f, 612–614 characteristics of, 532
pharmacodynamics of, 524–526, 525f, 5-LOX, 323, 325f drugs for
525t 5-LOX-activating protein (FLAP), 324, 325f antidepressants, 532–552, 549t–550t
pharmacokinetics of, 524, 524t Loxapine, 514f, 520t lithium, 526
recurrent depression treated with, 526 5-LOX inhibitors, 332 pathophysiology of, 533–536
schizoaffective disorder treated with, 526 Lp(a) hyperlipoproteinemia, 629t, 631 integration of hypotheses on, 536
schizophrenia treated with, 526 Lp(a) lipoprotein, 626–627 monoamine hypothesis in, 533,
Liver Lubiprostone, 1099, 1103 534–536, 535f
biotransformation in, 57–58 Lugol’s solution, 700, 701t neuroendocrine factors in, 536
contraceptives on, female hormonal, 733 Lumacaftor, 30 neurotrophic hypothesis in, 533f,
disease of. See also Hepatitis; specific types Lumefantrine, 919f, 920t, 928 533–534